Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
Phase 3 Completed
5,351 enrolled 8 charts
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Phase 1/2 Completed
93 enrolled
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
Phase 2 Completed
15 enrolled
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Completed
2,778 enrolled
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
Phase 3 Completed
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Phase 3 Completed
1,613 enrolled
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Phase 3 Unknown
1,871 enrolled
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
BETH
Phase 3 Terminated
3,509 enrolled
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Phase 1 Completed
50 enrolled
NEO-ZOTAC
Phase 3 Completed
250 enrolled
TC Avastin. ICORG 08-10, V6
Phase NA Completed
106 enrolled
TCHL Phase II
Phase 2 Completed
120 enrolled
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase 3 Unknown
1,206 enrolled 19 charts
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
Phase 1/2 Completed
129 enrolled
ABCSG 32
Phase 2 Completed
100 enrolled
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Phase 3 Completed
1,856 enrolled
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
Phase 2 Completed
76 enrolled 6 charts
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
Phase 2 Terminated
27 enrolled
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
Phase 2 Completed
89 enrolled
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
Phase 2 Completed
35 enrolled
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Phase 3 Completed
536 enrolled
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
Phase 3 Completed
2,411 enrolled
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
Phase 2 Completed
33 enrolled